Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 2315Neoplasms 1678Prostatic Neoplasms 1178Lung Neoplasms 908Colorectal Neoplasms 873Carcinoma, Non-Small-Cell Lung 848Leukemia, Myeloid, Acute 587Pancreatic Neoplasms 568Multiple Myeloma 542Carcinoma, Hepatocellular 510Brain Neoplasms 509Neoplasm Metastasis 456Head and Neck Neoplasms 454Melanoma 410Ovarian Neoplasms 404Glioblastoma 397Precursor Cell Lymphoblastic Leukemia-Lymphoma 390Stomach Neoplasms 370Uterine Cervical Neoplasms 355Squamous Cell Carcinoma of Head and Neck 355Rectal Neoplasms 336Recurrence 332Hematologic Neoplasms 323Sarcoma 322Colonic Neoplasms 316Lymphoma 310Triple Negative Breast Neoplasms 284Urinary Bladder Neoplasms 279Glioma 277Carcinoma, Renal Cell 277

Interventions

Androgen Antagonists 2relugolix 1niraparib 1Prednisone 1Docetaxel 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Metastatic Hormone-sensitive Prostate Cancer (mHSPC) × 1 year × Clear all
NCT06392841 2026-04-08

HARMONY

Hoosier Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07216248 2025-10-29

OPTIMAS

University of Utah

Phase 2 Recruiting
160 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡